Search | Clinical Trials Finder

Conditions: Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
Interventions: ED Sepsis Tracking Sheet; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Severe Sepsis, Septic Shock
Interventions: NICOM/FloTrac, Crystalloid Fluid Challenge; Device · Other
Lead sponsor: Santa Barbara Cottage Hospital; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Postoperative Complications
Interventions: Crystalloid, Colloid; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio • Mayfield Heights, Ohio

Conditions: Migraine Headache
Interventions: Normal saline (1000 mL), Control; Other
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Cerebral Edema, Diabetic Ketoacidosis
Interventions: 0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 1,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 13
States / cities: Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Palbociclib, Cetuximab, Cisplatin, Intensity-Modulated Radiation Therapy, Tumor biopsy, Peripheral blood draw; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Interventions: [¹⁴C]Etelcalcetide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
Interventions: Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD); Device · Drug
Lead sponsor: Nuwellis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 38
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
Interventions: Severe Sepsis Management Bundle; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 1 Month to 18 Years
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Lymphoma
Interventions: filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 104
States / cities: Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more

Conditions: Shock
Interventions: Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility, CURVES Questionnaire, Lactate Clearance, 500ml Normal Saline Bolus, Clinician Discretion Intravenous Fluid Management; Device · Behavioral · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cardiac Arrest
Interventions: Standard Care, Low Volume Hemofiltration, High Volume Hemofiltration; Other · Device
Lead sponsor: University of Washington; Other
Eligibility: 65 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Postoperative Nausea and Vomiting
Interventions: Intravenous fluid, D5LR or lactated ringers; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Subarachnoid Hemorrhage, Cerebral Vasospasm, Hyponatremia
Interventions: HTS 3%, Standard fluid management; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke Volume Variation, Diastolic Dysfunction
Interventions: Trans thoracic Ultrasound Examination, Intravenous fluid administration; Procedure · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetic Ketoacidosis
Interventions: intravenous fluid treatment; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Shock, Fluid Overload, Cardiac Output, Low
Interventions: Trendelenburg positioning VTI; Device
Lead sponsor: Lenox Hill Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes
Interventions: slow fluid rate, fast fluid rate; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Day to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypoxia
Interventions: Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2; Drug · Other · Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pregnancy, Labor Pain
Interventions: Group A Intravenous bolus of 1000 ml lactated ringers solution, Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate, Group C 125 mL/hr of lactated ringers, Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Intracerebral Hemorrhage
Interventions: Intravenous nicardipine hydrochloride; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Burns
Interventions: NICOM (non-invasive cardiac output monitor); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

ED Tracking Sheet Implementation

Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock

Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity

Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Electronic Application of a Severe Sepsis Screening Tool and Management Bundle

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)

Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest

A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting

Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:

Effect of Diastolic Dysfunction on Dynamic Cardiac Monitors

Cerebral Edema in Pediatric Diabetic Ketoacidosis

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

Fluid Resuscitation for Pediatric Diabetic Ketoacidosis

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Cardiac Output Monitoring in Burn Patients

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.